Eli Lilly CEO ‘definitely wants Mounjaro to be listed on the PBS’ Despite walking away from the deal earlier this year and price negotiations stalling, the drug’s manufacturer confirmed its intentions.
Price talks continue as Health Minister pushes for GLP-1 PBS access An agreed price is the main barrier to getting an expanded listing of the ‘revolutionary class of drugs’ on the PBS, Mark Butler has said in latest updates.
How do patients feel about using GLP-1 RAs? Experts are calling for standardised guidelines to improve patients’ expectation management, as overseas research examines reactions to the viral drugs.
Evidence ‘growing’ for GLP-1 RA use in asthma management: Expert There may be a role for semaglutide, but GPs remain key in managing asthma in patients, says a respiratory expert.
TGA issues warning against unapproved peptides The medicines regulator is sounding the alarm on unapproved peptide products amid ‘significant regulatory and public health’ risks.
PBAC issues update on subsidised access to GLP-1s As a PBS listing for Wegovy advances, the committee has detailed exactly how GLP-1 drugs could be accessed, advising a ‘slow and managed’ rollout.
RACGP pushes back on expanding weight-loss drugs for kids Ozempic manufacturer Novo Nordisk says children with obesity could benefit from the drugs, but the college warns holistic care will be replaced and health budgets blown.
TGA doubles down on fake GLP-1 warnings Its testing of several imported products confirmed they contain no GLP-1 or any GLP-1 analogues, despite being labelled as such.
New oral GLP-1 shows promise: Study New research found patients taking orforglipron have more weight loss than those taking semaglutide, as the manufacturer works to get the drug approved by the TGA.
GPs’ central role in Wegovy’s PBS recommendation How a small, dedicated team of GPs advocated for patients to have affordable access to ‘lifechanging’ obesity treatment.